Abstracts Archive - Page 889 of 2607 - ACR Meeting Abstracts

Abstract Number: 0789 • ACR Convergence 2020
Matrix Gla Protein (MGP) Modified with Malondialdehyde/Acetaldehyde Is Increased in Rheumatoid Arthritis and Cardiovascular Patients
Xiarepati Tieliwaerdi¹, Nozima Aripova¹, Michael Duryee¹, Xiaoting Jiang¹, Lynell Klassen², James O'Dell¹, Bryant England¹, Daniel Anderson¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Univerisity of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased cardiovascular disease (CVD) burden, dramatically increasing the risk of mortality. Circulating antibodies to Malondialdehyde-Acetaldehyde (MAA) modified…
Abstract Number: 0790 • ACR Convergence 2020
Vitamin D Polygenetic Risk Score and the Association with RA Autoantibodies Among First-Degree Relatives of RA Subjects
Elizabeth Bemis¹, Kendra Young², Jennifer Seifert³, Marie Feser⁴, Kevin D. Deane⁵, M Kristen Demoruelle⁶, James O'Dell⁷, Michael Weisman⁸, Peter Gregersen⁹, Richard Keating¹⁰, William Robinson¹¹, Jane Buckner¹², Carl Langefeld¹³, Joel Guthridge¹⁴, Judith James¹⁵, V Michael Holers⁴ and Jill Norris¹⁶, ¹Colorado School of Public Health Anschutz Medical Campus, Aurora, CO, ²University of Colorado Denver, Aurora, CO, ³UC Denver, Littleton, CO, ⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁵2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁶University of Colorado, Denver, CO, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹5. Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, ¹⁰Scripps Clinic/Scripps Green Hospital, La Jolla, CA, ¹¹Stanford University, Palo Alto, CA, ¹²Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹³Wake Forest School of Medicine, Winston Salem, NC, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, ¹⁶Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, Colorado
Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disease whose etiology remains largely unknown. Vitamin D has been widely studied due to its association with…
Abstract Number: 0791 • ACR Convergence 2020
Peficitinib Inhibits Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Yuzo Ikari¹, Takeo Isozaki¹, Kuninobu Wakabayashi¹ and Tsuyoshi Kasama², ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Koutou-ku Tokyo, Japan
Background/Purpose: Peficitinib is a novel Janus kinase (JAK) inhibitor developed for the treatment of rheumatoid arthritis (RA). Peficitinib has approved in 2019 in Japan, but…
Abstract Number: 0792 • ACR Convergence 2020
LY294002 Improves the Collagen-induced Arthritis by Inducing Neutrophil Apoptosis
Xuechan Huang¹, Tianwang Li¹, Shuyang Chen¹, Zhixiang Huang¹ and Junming Chen¹, ¹Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangdong, China (People's Republic)
Background/Purpose: Neutrophils play a central role in host defense, but they also play important effectors on acute and chronic inflammation. Neutrophil apoptosis is essential for…
Abstract Number: 0793 • ACR Convergence 2020
Topological Laser Capture Microscopy (LCM)-RNAseq to Map the Rheumatoid Arthritis (RA) Synovial Transcriptome
Benjamin Van Espen¹, Andrew Wilson¹, Gregory Seumois², Narayanan Perumal³, Robert Benschop⁴, Gary Firestein⁵, Nunzio Bottini⁵ and Stephanie Stanford¹, ¹University of California, San Diego, La Jolla, ²La Jolla Institute for Immunology, La Jolla, ³Eli Lilly, Indianapolis, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of California, San Diego, La Jolla, CA
Background/Purpose: Understanding pathogenic processes in the diseased tissue in rheumatoid arthritis (RA) is a critical step to defining disease pathogenesis and identifying novel therapeutic targets.…
Abstract Number: 0794 • ACR Convergence 2020
Peripheral Blood T and B Lymphocyte Subsets in Arthritis in the Elderly
Aina Teniente-Serra¹, Lourdes Mateo², Agueda Prior³, Monica Guma⁴, Eva Martinez-Caceres¹ and Melania Martinez-Morillo⁵, ¹Department of Immunology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, ²Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, ³Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁴Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA, ⁵Hospital Germans Trias i Pujol, Barcelona, Spain
Background/Purpose: Multiple lymphocyte subsets like T and B cells have been connected to joint infiltration and inflammation in rheumatoid arthritis (RA). Identification of leucocyte subsets…
Abstract Number: 0795 • ACR Convergence 2020
Minimum Clinically Important Improvement in Patients with Rheumatoid Arthritis Associates with Gut Microbiome
Vinod Gupta¹, Kevin Cunningham², Benjamin Hur¹, John Davis¹ and Jaeyun Sung¹, ¹Mayo Clinic, Rochester, MN, ²University of Minnesota, Minneapolis, MN
Background/Purpose: Within the past decade, there have been several major discoveries in cross-sectional gut microbiome studies suggesting that dysbiosis of the gut microbiota is a…
Abstract Number: 0796 • ACR Convergence 2020
Development of a Tool to Assess Synovial Tissue Infiltrates and Derive Histological Pathotype in Inflammatory Arthritis: Relationship to Clinical and Ultrasound Variables
Hayley Carr¹, Ilfita Sahbudin¹, Mark Maybury¹, Bernard Dyke², Jason Turner³, Nicola Gullick⁴, Karim Raza⁵, Dagmar Scheel-Toellner¹ and Andrew Filer¹, ¹Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ²Institute of Inflammation and Ageing, University of Birmingham, Birmingham, England, United Kingdom, ³Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁴University Hospitals Coventry & Warwickshire, Coventry, United Kingdom, ⁵Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom
Background/Purpose: Evidence suggests that histological pathotypes are linked to pathogenic mechanisms in inflammatory arthritis and may be useful as biomarkers of outcome. The frequently used…
Abstract Number: 0797 • ACR Convergence 2020
Comparison of the Efficacy and Safety of Janus Kinase Inhibitors and DMARDs in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis
Adela Castro¹, Jesus Diaz² and Guillermo Quiceno³, ¹UT Southwestern, Dallas, TX, ²Universidad de los Andes, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Janus Kinase (JAK) inhibitors have shown long term benefit in patients with active RA with inadequate response to conventional or biologic DMARDs (1). Due to…
Abstract Number: 0798 • ACR Convergence 2020
A Randomized, Double-blind Phase 3 Study Comparing the Efficacy, Safety and Immunogenicity of PF-06410293 (Abrilada™), an Adalimumab (ADL) Biosimilar, and Reference ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92
Roy Fleischmann¹, Daniel Alvarez², Amy Bock³, Carol Cronenberger⁴, Ivana Vranic⁵, Wuyan Zhang⁶ and Rieke Alten⁷, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Pfizer, Collegeville, PA, ³Pfizer, Cambridge, MA, ⁴Pfizer, Collegeville, ⁵Pfizer, Tadworth, United Kingdom, ⁶Pfizer, New York, ⁷Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany
Background/Purpose: To evaluate the long-term safety, immunogenicity (IG), and efficacy of the adalimumab (ADL) biosimilar, PF-06410293 (ADL-PF), in patients (pts) with moderate to severe active…
Abstract Number: 0799 • ACR Convergence 2020
Effectiveness of Electronic Drug Monitoring Feedback in Order to Increase Adherence in RA Patients Starting with a Biological DMARD
Renske Hebing¹, Wouter Bos¹, Mike Nurmohamed² and Bart van den Bemt³, ¹Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Medication non-adherence in rheumatoid arthritis (RA) is associated with disease flares, increased disability and increased costs. Electronic Monitoring Feedback (EMF) to improve adherence has…
Abstract Number: 0800 • ACR Convergence 2020
A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
Jonathan Kay¹, Janusz Jaworski², Rafal Wojciechowski³, Piotr Wiland⁴, Anna Dudek⁵, Marek Krogulec⁶, Slawomir Jeka⁷, Agnieszka Zielinska⁸, Jakub Trefler⁹, Katarzyna Bartnicka-Maslowska¹⁰, Magdalena Krajewska-Wlodarczyk¹¹, Piotr Klimiuk¹², Daniel Furst*¹³, SangJoon Lee¹⁴, YunJu Bae¹⁴, GoEun Yang¹⁴, JaeKyoung Yoo¹⁴, HyunJin Lee¹⁴ and Edward C Keystone¹⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Reumatika-Centrum Reumatologii, Warsaw, Poland, ³University Hospital No 2, Bydgoszcz, Poland, ⁴Medical Univeristy, Wroclaw, Poland, ⁵Centrum Medyczne AMED, Warsaw, Poland, ⁶Rheumatology Clinic NZOZ Lecznica MAK-MED, Nadarzyn, Poland, ⁷2nd Univ Hospital, CM UMK, Bydgoszcz, Poland, ⁸Medycyna Kliniczna Marzena Waszczak-Jeka, Warsaw, Poland, ⁹Reuma Centrum, Warsaw, Poland, ¹⁰Centrum Medyczne AMED oddzial w Łodzi, Łódź, Poland, ¹¹University of Warmia and Mazury, Olsztyn, Poland, ¹²Medical University of Białystok and Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Białystok, Poland, ¹³Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ¹⁴Celltrion, Inc., Incheon, Republic of Korea, ¹⁵Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: CT-P17 (100 mg/mL) is the first proposed biosimilar of the high concentration and citrate-free formulation of reference adalimumab. The purpose of this study was…
Abstract Number: 0801 • ACR Convergence 2020
The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Xue Han², Joe Zhuo², Amy Schrader¹, Nicole Middaugh¹, Page Moore¹ and Vadim Khaychuk², ¹Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
Abstract Number: 0802 • ACR Convergence 2020
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness
Yoshiya Tanaka¹, Hisashi Yamanaka², Leslie Harrold³, Tin-chi Lin³, Ekta Agarwal⁴, Jose L Rivas⁵, Naonobu Sugiyama⁶, Jeffrey Greenberg⁷ and Mitsumasa Kishimoto⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ³Corrona, LLC, Waltham, MA, ⁴Pfizer, Inc., Princeton Jct, NJ, ⁵Pfizer SLU, Madrid, Spain, ⁶Pfizer Japan Inc, Tokyo, Japan, ⁷Corrona, LLC and NYU School of Medicine, Waltham, MA, ⁸Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: There are several conventional synthetic, targeted synthetic and biological disease-modifying anti-rheumatic medications (DMARDs) approved for the treatment of rheumatoid arthritis (RA) in Japan. Little…
Abstract Number: 0803 • ACR Convergence 2020
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Safety
Mitsumasa Kishimoto¹, Yoshiya Tanaka², Leslie Harrold³, Alina Onofrei³, Christine Barr⁴, Ekta Agarwal⁵, Jose L Rivas⁶, Naonobu Sugiyama⁷, Jeffrey Greenberg⁸ and Hisashi Yamanaka⁹, ¹Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Albany, NY, ⁵Pfizer, Inc., Princeton Jct, NJ, ⁶Pfizer SLU, Madrid, Spain, ⁷Pfizer Japan Inc, Tokyo, Japan, ⁸Corrona, LLC and NYU School of Medicine, Waltham, MA, ⁹Sanno Medical Center, Tokyo, Japan, Tokyo, Japan
Background/Purpose: There is limited information on the real-world safety of disease-modifying anti-rheumatic drugs (DMARDs) approved for treating rheumatoid arthritis (RA) in Japan. Using a Japanese…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].